## **Core Concept**
Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer. It targets a specific protein that is overexpressed in some cancer cells. The mechanism of action involves binding to this protein, which can help slow or stop the growth of the cancer cells.

## **Why the Correct Answer is Right**
Trastuzumab is specifically targeted against the **HER2/neu receptor**. This receptor is a member of the human epidermal growth factor receptor family and is overexpressed in some breast cancers. By binding to the HER2 protein, trastuzumab blocks the receptor's signaling, which in turn inhibits the proliferation of cancer cells that overexpress HER2. The HER2/neu receptor is also known as ERBB2.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while there are various targets for monoclonal antibodies in cancer therapy, trastuzumab's specific target is not listed here.
- **Option B:** This option is incorrect as it does not accurately represent the target of trastuzumab.
- **Option C:** This option might seem plausible but is incorrect because it does not specify HER2/neu, which is the correct target.
- **Option D:** This option is incorrect because it is not the correct target for trastuzumab.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **HER2-positive breast cancers** account for about 20% of breast cancers. Trastuzumab is a crucial drug in the treatment of HER2-positive breast cancer, highlighting the importance of testing for HER2 status in breast cancer patients to guide therapy.

## **Correct Answer:** B. HER2/neu receptor.